Buyck, Julien, 1980-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Julien M Buyck researcher
VIAF ID: 205004580 (Personal)
Permalink: http://viaf.org/viaf/205004580
Preferred Forms
-
100 1 _
‡a
Buyck, Julien
‡d
1980-...
-
100 1 _
‡a
Buyck, Julien,
‡d
1980-....
-
100 0 _
‡a
Julien M Buyck
‡c
researcher
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Apport de la modélisation semi-mécanistique dans l'étude pharmacocinétique/pharmacodynamique des antibiotiques seuls et en combinaison dans la lutte contre les bactéries résistantes |
|
| L’ axe microbiote-intestin-cerveau dans les maladies neurodégénératives et psychiatriques et la nouvelle place des psychobiotiques dans la stratégie thérapeutique |
|
| Contribution of pharmacokinetic/pharmacodynamic modelling for studying antibiotic combinations and fight against resistance emergence. |
|
| Contribution to the understanding of resistance mechanisms to new beta-lactams observed in clinical strains of Gram-negative bacilli : inputs from molecular biology and pharmacokinetic/pharmacodynamic analysis. |
|
| Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1β secretion in a model of human THP-1 monocytes. |
|
| Impact de la résistance aux inhibiteurs de LpxC dans la pathogenèse de la peste |
|
| In Vitro Models for the Study of the Intracellular Activity of Antibiotics. |
|
| Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability |
|
| Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation |
|
| Mechanisms and PK/PD modelling of MCR-1-induced adaptive resistance in Enterobacteriaceae |
|
| Microbiote intestinal et SARS-CoV-2 |
|
| New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides |
|
| Optimisation biopharmaceutique de l'antibiothérapie pour le traitement des infections pulmonaires à Mycobacterium abscessus : intérêt de la nébulisation et des combinaisons antibiotiques. |
|
| Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam |
|
| Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa |
|
| Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus |
|
| Prévalence et expression des systèmes de sécrétion de type III et de type IV et de leurs effecteurs chez Pseudomonas aeruginosa |
|
| Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis |
|
| Rôles du calcium et des transports ioniques de l'épithelium des voies aériennes dans la réponse à l'agression septique par Pseudomonas aeruginosa |
|
| RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria |
|
| Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms. |
|
